Novartis AG raised its mid-term sales growth forecast as the Swiss drugmaker narrows its focus on innovative medicines with the highest profit potential.

Sales should increase 5% annually through 2027, the Basel-based company said Tuesday. The core operating margin should be about 40% or more by 2027.